Breaking News Instant updates and real-time market news.

FB

Facebook

$134.89

-3 (-2.18%)

, CNAT

Conatus

$2.13

-2.38 (-52.77%)

10:33
12/06/18
12/06
10:33
12/06/18
10:33

On The Fly: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Facebook (FB) downgraded to Hold from Buy at Stifel with analyst Scott Devitt saying Facebook has made too many enemies, including politicians, regulators, technology leaders, consumers, and employees, to not experience "long-term negative ramifications on its business." 2. Conatus (CNAT) downgraded to Hold from Buy at Stifel with analyst Stephen Willey saying the Encore-PH trial missed its pre-specified primary endpoint but post-hoc analyses demonstrated a trend towards statistically significant/emricasan-mediated improvements in patients with compensated cirrhosis and elevated baseline hepatic venous pressure gradient values. 3. BHP Billiton (BHP) downgraded to Neutral from Overweight at JPMorgan with analyst Lyndon Fagan saying the stock has outperformed Rio Tinto (RIO) by 10% year-to-date, and is now trading "within range of our valuation." 4. Toll Brothers (TOL) downgraded to Sector Perform from Outperform at RBC Capital with analyst Michael Dahl citing a "sharper than expected weakness in orders and likelihood of further near-term declines," with softer margin assumptions attributed to a weaker outlook for orders. 5. Bluebird Bio (BLUE) downgraded to Neutral from Overweight at Piper Jaffray with analyst Tyler Van Buren saying the company is "incredibly innovative" company and bb2121 and LentiGlobin are essentially curing some patients, but the benefits "are not without serious risks." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

FB

Facebook

$134.89

-3 (-2.18%)

CNAT

Conatus

$2.13

-2.38 (-52.77%)

BHP

BHP Group

$44.38

-1.49 (-3.25%)

TOL

Toll Brothers

$33.41

0.34 (1.03%)

BLUE

Bluebird Bio

$108.35

-5.3 (-4.66%)

  • 13

    Dec

FB Facebook
$134.89

-3 (-2.18%)

11/26/18
MKMP
11/26/18
NO CHANGE
Target $190
MKMP
Buy
MKM Partners lowers price targets on Alphabet and Facebook
MKM Partners analyst Rob Sanderson lowers his price target on Alphabet (GOOGL) to $1,365 from $1,465 and on Facebook (FB) to $190 from $230 as part of his broader research note for the Internet Applications and Media sector. The analyst states that both of these stocks have been underperforming the Nasdaq on 1-month, 3-month, and year-to-date basis, but believes that Alphabet's underperformance has more to do with a rotation away from growth given its "remarkably consistent" performance and its expected moderating traffic acquisition rate costs. Sanderson says that while Facebook stock is the "furthest from its intrinsic value", it continues to face a "challenging event path with engagement shift toward lower monetizing apps" and the expected cost increase to build greater "safety and security competencies". He also believes that Facebook business model will normalize at "much lower profit margin" because of these added costs. The analyst keeps Alphabet and Facebook ratings at Buy. As part of his research note, Sanderson also maintains a Buy rating on Twitter (TWTR) with a price target of $43. The analyst contends that the company has "compelling upside potential as monetization catches up to engagement growth", with added optionality coming from potential "service breaks-through to the mass market."
12/05/18
STFL
12/05/18
DOWNGRADE
STFL
Hold
Facebook downgraded to Hold from Buy at Stifel
12/05/18
STFL
12/05/18
DOWNGRADE
STFL
Hold
Facebook downgraded to Hold from Buy at Stifel
Stifel analyst Scott Devitt downgraded Facebook to Hold from Buy and maintained a $150 price target on shares. The analyst wrote in a research note titled 'A Company (Still) In Crisis; Lowering Rating To Hold' that Facebook has made too many enemies, including politicians, regulators, technology leaders, consumers, and employees, to not experience "long-term negative ramifications on its business." Devitt added that the political and regulatory blowback could lead to restrictions on how can Facebook operate. Facebook shares closed down 2.2% to $137.93 on Tuesday, and did not trade today due to the market closure for the day of mourning.
12/06/18
GUGG
12/06/18
INITIATION
Target $150
GUGG
Neutral
Facebook initiated with a Neutral due to challenges at Guggenheim
Guggenheim analyst Michael Morris initiated Facebook with a Neutral and $150 price target saying he expects challenges related to privacy, regulation, and operations monetization to continue to weight on investor sentiment and limit multiple expansion.
CNAT Conatus
$2.13

-2.38 (-52.77%)

12/06/18
HCWC
12/06/18
NO CHANGE
Target $14
HCWC
Buy
Conatus study 'thoroughly positive' despite endpoint miss, says H.C. Wainwright
Conatus Pharmaceuticals reported "yet another thoroughly positive study of emricasan masked by the failure to meet the overall primary endpoint," H.C. Wainwright analyst Ed Arce tells investors in a research note. He lowered his price target for the shares to $14 from $15 and keeps a Buy rating on the name. The analyst expects the stock to drop over 10% today as "some investors will undoubtedly look no further at yesterday's release of the ENCORE-PH top-line results, than to see that the study missed its primary endpoint." Arce, however, believes there is "actually a lot to like in these results." Roughly 75% of patients across the study had compensated cirrhosis, and the mean baseline HVPG reading across the three emricasan dose groups was approximately 17 mmHg, meaningfully lower than the mean baseline HVPG of 21.3 mmHg in the previous pilot study of portal hypertension patients which showed improvements in just four weeks, says the analyst.
12/06/18
OPCO
12/06/18
NO CHANGE
Target $10
OPCO
Outperform
Conatus price target lowered to $10 from $14 at Oppenheimer
Oppenheimer analyst Jay Olson lowered his price target for Conatus to $10 from $14 after the company announced top-lined results from the Phase 2b ENCORE-PH trial in 240 patients with compensated or early decompensated NASH cirrhosis and severe portal hypertension. The analyst notes that the trial did not meet the primary endpoint of a statistically significant decrease in mean HVPG versus placebo in all patients. However, in compensated NASH cirrhosis patients, post hoc analyses demonstrated consistent improvements in mean HVPG at week 24 over baseline, he points out. Olson believes development in compensated patients is on the table post all Phase 2 readouts. He reiterates an Outperform rating on the shares.
12/06/18
STFL
12/06/18
DOWNGRADE
Target $4
STFL
Hold
Stifel downgrades Conatus to Hold after trial misses endpoint
Stifel analyst Stephen Willey downgraded Conatus Pharmaceuticals to Hold from Buy and cut his price target for the shares to $4 from $10. The Encore-PH trial missed its pre-specified primary endpoint but post-hoc analyses demonstrated a trend towards statistically significant/emricasan-mediated improvements in patients with compensated cirrhosis and elevated baseline hepatic venous pressure gradient values, Willey tells investors in a research note. However, despite this trend, the analyst believes the results 'still highlight a number of lingering uncertainties," including a lack of dose-dependency across efficacy/biomarker data, dose-selection, and the utilization of "inherently variable endpoints further complicated by small patient numbers."
12/06/18
RHCO
12/06/18
NO CHANGE
Target $12
RHCO
Buy
Conatus price target lowered to $12 from $20 at SunTrust
SunTrust analyst John Boris lowered his price target on Conatus (CNAT) to $12 after yesterday's release of the ENCORE-PH top-line results showing that a phase-2b study of Emricasan missed its primary endpoint. The analyst keeps his Buy rating however, stating that the drug still showed a "clinically meaningful" benefit in NASH" while pushing out the expected launch of the program to 2023, citing the anticipated evaluation of data for a potential combination with one of Novartis's (NVS) FXR agonists.
BHP BHP Group
$44.38

-1.49 (-3.25%)

12/06/18
JPMS
12/06/18
DOWNGRADE
JPMS
Neutral
BHP Billiton downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Lyndon Fagan downgraded BHP Billiton (BHP) to Neutral and lowered his price target for the shares to A$35 from A$38. The stock has outperformed Rio Tinto (RIO) by 10% year-to-date, and is now trading "within range of our valuation," Fagan tells investors in a research note. He keeps an Overweight rating on Rio saying the stock is "now cheaper than BHP across a range of valuation metrics."
12/06/18
GSCO
12/06/18
UPGRADE
GSCO
Conviction Buy
BHP Billiton upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman analyst Paul Young added BHP Billiton to the Conviction Buy List saying shares are undervalued despite China weakness. Young sees further upside from share buybacks, superior margins, and non-core divestment potential.
09/10/18
DBAB
09/10/18
DOWNGRADE
DBAB
Hold
BHP Billiton downgraded to Hold from Buy at Deutsche Bank
09/10/18
JPMS
09/10/18
UPGRADE
JPMS
Overweight
Rio Tinto upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Dominic O'Kane upgraded Rio Tinto (RIO) to Overweight while lowering his price target for the shares to 4,850p from 4,950p. The analyst finds the current valuation attractive with Rio trading at a 15% discount to BHP Billiton (BHP). Further, he believes China's fiscal loosening and infrastructure investment, as well as its anti-pollution steel capacity shut downs, will boost demand for high quality Australian iron ore.
TOL Toll Brothers
$33.41

0.34 (1.03%)

12/06/18
RBCM
12/06/18
DOWNGRADE
RBCM
Sector Perform
Toll Brothers downgraded to Sector Perform from Outperform at RBC Capital
12/06/18
RBCM
12/06/18
DOWNGRADE
Target $37
RBCM
Sector Perform
Toll Brothers downgraded to Sector Perform at RBC Capital on order weakness
As reported earlier, RBC Capital analyst Michael Dahl downgraded Toll Brothers to Sector Perform from Outperform and lowered his price target to $37 from $38. The analyst cites a "sharper than expected weakness in orders and likelihood of further near-term declines", with softer margin assumptions attributed to a weaker outlook for orders. Dahl adds that while Toll Brothers outperformed its peer group over the past few months and its valuation remains relatively cheap, the recent order trends are making him more cautious about the company's fundamental outlook.
10/25/18
EVER
10/25/18
UPGRADE
Target $39
EVER
Outperform
Toll Brothers upgraded to Outperform on valuation at Evercore ISI
As previously reported, Evercore ISI upgraded KB Home to Outperform from In Line and maintained a $39 price target. Analyst Stephen Kim said the Homebuilders group has sold off sharply and is now trading at a 20% discount to book values, a traditional buy signal.
12/06/18
WEDB
12/06/18
NO CHANGE
Target $36
WEDB
Neutral
Toll Brothers price target lowered to $36 from $44 at Wedbush
Wedbush analyst Jay McCanless lowered his price target for Toll Brothers to $36 from $44 as he shifts to a FY20 valuation from FY19. According to management, sales activity improved sequentially through the quarter but softened from October into November, he contends, adding that he trimmed his order growth expectations for FY19 as a result. McCanless is also adopting a more cautious outlook on community growth for the full year. He reiterates a Neutral rating on the shares.
BLUE Bluebird Bio
$108.35

-5.3 (-4.66%)

12/06/18
PIPR
12/06/18
DOWNGRADE
Target $120
PIPR
Neutral
Bluebird Bio downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren downgraded Bluebird Bio to Neutral and cut his price target for the shares to $120 from $240. The stock closed Tuesday down $2.85 to $113.65. The company is "incredibly innovative" company and bb2121 and LentiGlobin are essentially curing some patients, but the benefits "are not without serious risks," Van Buren tells investors in a research note. And while these are risks worth taking for octorefractory multiple myeloma patients with just days to live, the proposition for beta thalassemia and sickle cell patients "is much more difficult," says the analyst. Further, Van Buren believes that as LentiGlobin launches next year, the "exuberance and hope" of clinical development will soon transition to "high expectations for commercial performance." Key opinion leaders agree that broad uptake of LentiGlobin will be challenging, admits the analyst. He lowered his estimates for LentiGlobin and downgraded Bluebird Bio to Neutral.
12/03/18
ADAM
12/03/18
NO CHANGE
ADAM
Canaccord has positive expectations for Bluebird after bb 21217 data released
Canaccord analyst John Newman maintained a Buy rating and $250 price target on Bluebird Bio, after the company recently released bb 21217 data. Newman has continued positive expectations for the active programs, and for bb2121's clinical progression. He added that "given the previous bb2121 dose response data, we continue to expect strong response data from the ongoing Phase 2 KarMMa trial, the ongoing Phase 1 CRB-401 trial in RRMM, and future Phase 3 trial." The analyst also noted that Bluebird reported cash and marketable securities of ~$2B, which he believes should be able to fund the company to profitability.
12/03/18
JANY
12/03/18
NO CHANGE
Target $170
JANY
Buy
Janney says Bluebird LentiGlobin updates consistent, bb21217 data promising
Janney Montgomery Scott analyst Yun Zhong said the updated data presented at ASH by Bluebird Bio continues to demonstrate sustained clinical benefit and an overall benign safety profile of LentiGlobin in both beta-thalassemia and sickle cell disease. The case of myelodysplastic syndrome that was reported was assessed as not related to LentiGlobin, but possibly related to preconditioning with busulfan, noted Zhong. Additionally, initial data from the study of bb21217 demonstrates "promising signs" of improvement compared to bb2121, though longer follow up is still required, said the analyst. Zhong keeps a Buy rating on Bluebird Bio shares with a $170 fair value estimate.
12/02/18
PIPR
12/02/18
NO CHANGE
Target $80
PIPR
Overweight
GBT may benefit from Bluebird potential safety concerns, says Piper Jaffray
Piper Jaffray analyst Danielle Brill notes that while the major catalyst for Global Blood Therapeutics (GBT) remains the regulatory update for voxelotor now expected tomorrow morning, she thinks the stock will also benefit from Bluebird Bio's (BLUE) setback with its LentiGlobin gene therapy for SCD, namely a patient that developed MDS 3 years post LentiGlobin treatment. Global Blood Therapeutics and Bluebird Bio are two of the major players in the SCD space and Brill thinks patients and docs will prefer the former's voxelotor "now more than ever," given the potential safety liabilities of gene therapy. The analyst reiterates an Overweight rating and $80 price target on Global Blood's shares.

TODAY'S FREE FLY STORIES

EE

El Paso Electric

$66.83

0.13 (0.19%)

, JPM

JPMorgan

$120.02

0.25 (0.21%)

13:29
09/19/19
09/19
13:29
09/19/19
13:29
Hot Stocks
El Paso Electric investors approve deal to be acquired by IIF »

El Paso Electric Company…

EE

El Paso Electric

$66.83

0.13 (0.19%)

JPM

JPMorgan

$120.02

0.25 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 15

    Oct

  • 27

    Oct

ADVM

Adverum Biotechnologies

$6.47

0.28 (4.52%)

13:25
09/19/19
09/19
13:25
09/19/19
13:25
Options
Adverum Biotechnologies call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Oct

13:25
09/19/19
09/19
13:25
09/19/19
13:25
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

TDOC

Teladoc

$69.70

2.22 (3.29%)

13:25
09/19/19
09/19
13:25
09/19/19
13:25
Conference/Events
Teladoc participates in a conference call with Citigroup »

Citigroup holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

FANG

Diamondback Energy

$97.34

-0.89 (-0.91%)

13:25
09/19/19
09/19
13:25
09/19/19
13:25
Conference/Events
Diamondback Energy participates in a conference call with JPMorgan »

Conference call with CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 02

    Oct

PEI

Pennsylvania REIT

$5.65

0.43 (8.24%)

13:23
09/19/19
09/19
13:23
09/19/19
13:23
Hot Stocks
Pennsylvania REIT jumps over 8% after insiders purchase shares »

Shares of Pennsylvania…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDR

McDermott

$1.66

-0.5 (-23.15%)

13:19
09/19/19
09/19
13:19
09/19/19
13:19
Periodicals
McDermott CEO cancels appearance after hiring adviser, Bloomberg reports »

McDermott International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
09/19/19
09/19
13:17
09/19/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
09/19/19
09/19
13:16
09/19/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHUN

Phunware

$1.97

0.21 (11.93%)

13:10
09/19/19
09/19
13:10
09/19/19
13:10
Hot Stocks
Phunware jumps over 17% after saying it will launch IEO of Phun tokens »

Earlier on Thursday,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MACK

Merrimack

$5.58

0.22 (4.10%)

13:10
09/19/19
09/19
13:10
09/19/19
13:10
Hot Stocks
Newtyn Management discloses 8.8% stake in Merrimack Pharmaceuticals »

Noah Levy's Newtyn…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

13:10
09/19/19
09/19
13:10
09/19/19
13:10
General news
Treasury Action: the markets are likely to settle down, awaiting the next big thing »

Treasury Action: the…

MAR

Marriott

$130.22

0.07 (0.05%)

13:08
09/19/19
09/19
13:08
09/19/19
13:08
Hot Stocks
Marriott announces agreement to bring Ritz-Carlton brand to Montenegro »

Marriott International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:06
09/19/19
09/19
13:06
09/19/19
13:06
General news
10-Yr TIPS Auction Total Amount data reported »

10-Yr TIPS Auction Total…

13:06
09/19/19
09/19
13:06
09/19/19
13:06
General news
10-Yr TIPS Auction Coupon Rate data reported »

10-Yr TIPS Auction Coupon…

WBA

Walgreens Boots Alliance

$54.79

0.365 (0.67%)

, GOOGL

Alphabet Class A

$1,237.98

5.02 (0.41%)

13:06
09/19/19
09/19
13:06
09/19/19
13:06
Hot Stocks
Walgreens to test on-demand drone delivery service with Wing »

Walgreens (WBA) and Wing,…

WBA

Walgreens Boots Alliance

$54.79

0.365 (0.67%)

GOOGL

Alphabet Class A

$1,237.98

5.02 (0.41%)

GOOG

Alphabet

$1,238.09

5.46 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Oct

GOOG

Alphabet

$1,238.27

5.64 (0.46%)

, GOOGL

Alphabet Class A

$1,238.02

5.06 (0.41%)

13:05
09/19/19
09/19
13:05
09/19/19
13:05
Hot Stocks
Wing partners with FedEx Express, Walgreens to launch drone delivery service »

Wing Aviation LLC, an…

GOOG

Alphabet

$1,238.27

5.64 (0.46%)

GOOGL

Alphabet Class A

$1,238.02

5.06 (0.41%)

FDX

FedEx

$150.71

-0.2 (-0.13%)

WBA

Walgreens Boots Alliance

$54.80

0.38 (0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 30

    Sep

  • 01

    Oct

  • 27

    Oct

  • 13

    Nov

  • 17

    Dec

EROS

Eros International

$3.43

0.88 (34.51%)

13:04
09/19/19
09/19
13:04
09/19/19
13:04
Hot Stocks
Eros teams with Microsoft on 'next generation' online video platform »

Earlier today, Eros…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSK

GlaxoSmithKline

$41.47

0.41 (1.00%)

13:04
09/19/19
09/19
13:04
09/19/19
13:04
Hot Stocks
GlaxoSmithKline granted orphan status for biliary cholangitis treatment »

The FDA granted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Sep

  • 02

    Oct

GRUB

GrubHub

$61.36

-2.42 (-3.79%)

12:55
09/19/19
09/19
12:55
09/19/19
12:55
Options
GrubHub put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:55
09/19/19
09/19
12:55
09/19/19
12:55
General news
FX Action: USD-CAD »

FX Action: USD-CAD has…

XGN

Exagen

$0.00

(0.00%)

12:54
09/19/19
09/19
12:54
09/19/19
12:54
Syndicate
Breaking Syndicate news story on Exagen »

Exagen opens at $16.80,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

XGN

Exagen

$0.00

(0.00%)

12:50
09/19/19
09/19
12:50
09/19/19
12:50
Syndicate
Breaking Syndicate news story on Exagen »

Exagen indicated to open…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

CAIXY

CaixaBank

$0.00

(0.00%)

12:46
09/19/19
09/19
12:46
09/19/19
12:46
Periodicals
France's CNP, CaixaBank near $1.7B insurance pact, Reuters reports »

France's CNP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IQ

iQIYI

$19.00

0.06 (0.32%)

12:45
09/19/19
09/19
12:45
09/19/19
12:45
Options
iQiyi call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.